证券日报网讯1月13日，葵花药业（002737）在互动平台回答投资者提问时表示，为确保信息披露的公 平性及合规性，公司将在定期报告中披露对应时点的股东信息，请及时查阅。最新股东数据请以公司在 中国证监会指定信息披露媒体发布的定期报告为准。 ...

Group 1 - The core viewpoint of the news is that Kew Flower Pharmaceutical experienced a slight increase in stock price and trading volume, with notable changes in financing and stockholder dynamics [1][2] Group 2 - As of January 9, Kew Flower Pharmaceutical's stock price rose by 0.74%, with a trading volume of 37.18 million yuan. The financing buy-in amount was 2.92 million yuan, while the financing repayment was 2.43 million yuan, resulting in a net financing buy-in of 489,200 yuan [1] - The total financing and securities balance for Kew Flower Pharmaceutical reached 135 million yuan, with the financing balance accounting for 1.51% of the circulating market value, indicating a low level compared to the past year [1] - On the short-selling side, Kew Flower Pharmaceutical had a short-selling repayment of 100 shares and no short-selling sales, with a short-selling balance of 2.05 million yuan, which is above the 80th percentile level over the past year, indicating a high level [1] Group 3 - As of December 31, the number of shareholders for Kew Flower Pharmaceutical was 48,000, a decrease of 2.04% from the previous period, while the average circulating shares per person increased by 2.08% to 12,166 shares [2] - For the period from January to September 2025, Kew Flower Pharmaceutical reported a revenue of 1.684 billion yuan, a year-on-year decrease of 43.24%, and a net profit attributable to shareholders of -33.54 million yuan, a decrease of 105.72% year-on-year [2] - Since its A-share listing, Kew Flower Pharmaceutical has distributed a total of 4.045 billion yuan in dividends, with 1.752 billion yuan distributed in the last three years [2] Group 4 - As of September 30, 2025, among the top ten circulating shareholders of Kew Flower Pharmaceutical, E Fund CSI Dividend ETF ranked fifth with 3.4008 million shares, an increase of 239,600 shares from the previous period [2] - Hong Kong Central Clearing Limited ranked seventh with 2.8412 million shares, a decrease of 128,700 shares from the previous period [2] - The eighth largest circulating shareholder, China Merchants CSI Dividend ETF, held 2.8382 million shares, an increase of 234,900 shares, while the ninth largest, Southern CSI 1000 ETF, held 2.6757 million shares, a decrease of 20,300 shares [2]

Group 1 - The core point of the article is that Kew Flower Pharmaceutical has reported that as of December 31, 2025, the number of shareholders is expected to reach 48,000 households [2]

Group 1 - The core point of the article is that Kew Flower Pharmaceutical (002737.SZ) has appointed Mr. Zhao Peng as the vice president, effective from the date of the board's approval until the current board's term ends [1] Group 2 - The decision was made during the 15th meeting of the 5th board of directors held on December 30, 2025 [1] - The appointment was approved after a qualification review by the nomination committee during its third meeting [1]

证券代码：002737 证券简称：葵花药业 公告编号：2025-085 葵花药业集团股份有限公司 关于使用闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 经葵花药业集团股份有限公司（以下简称"公司"）第五届董事会第六次会 议、第五届监事会第四次会议、公司 2024 年年度股东大会审议通过，公司决定 使用闲置自有资金额度不超过 20 亿元人民币进行现金管理，上述额度自股东大 会审议通过之日起 12 个月内有效，有效期内，上述额度可滚存使用。 授权董事长在上述期限和额度内，行使本次现金管理的决策权并签署相关法 律文件，由公司财务部门负责具体实施。 有关上述具体内容详见《上海证券报》、《证券日报》、巨潮资讯网 （http:www.cninfo.com.cn）公司公告。 一、本次进行现金管理的实施进展情况 根据上述决议，公司于近日使用闲置自有资金 35,000 万元购买了部分理财 产品，具体情况如下： | 序 | 签约机构 | 产品名称 | 产品类型 | 金额 | 起息日 | 到期日 | 预期年化收 | 资金 | | --- | - ...

证券代码：002737 证券简称：葵花药业 公告编号：2025-084 葵花药业集团股份有限公司 关于全资子公司受让美沙拉秦肠溶片上市许可 及相关生产技术的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、交易概述 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）于 2025 年 12 月 30 日召开第五届董事会第十五次会议，审议通过《关于全资子公司受让美 沙拉秦肠溶片上市许可及相关技术的议案》。为进一步丰富产品管线、持续巩固 公司在消化系统用药优势地位，增强公司整体抗风险能力，实效落地"一老"战 略，公司同意全资子公司葵花药业集团佳木斯鹿灵制药有限公司（以下简称"鹿 灵葵花"）以人民币 3,400 万元(含税)受让合肥立方制药股份有限公司（以下简 称"立方制药"）持有的美沙拉秦肠溶片（0.5g 规格）的药品上市许可及相关 生产技术。 本次受让药品上市许可事项涉及变更上市许可持有人，变更事宜尚需国家药 品监督管理局审批。 本次交易不构成关联交易，不属于《上市公司重大资产重组管理办法》所规 定的重大资产重组。 本次交易事项在董事会审议权限范围内 ...

证券代码：002737 证券简称：葵花药业 公告编号：2025-083 葵花药业集团股份有限公司 关于副总经理辞职及聘任公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、副总经理辞职情况 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）董事会于近 日收到公司副总经理郭超先生、海洋先生提交的书面辞职报告。郭超先生因个人 原因申请辞去公司副总经理职务，辞职后仍担任公司控股子公司相关职务；海洋 先生因个人原因申请辞去公司副总经理职务，辞职后将不再担任公司（含子公司） 任何职务。 公司董事会对郭超先生、海洋先生在任职期间为公司发展所作出的贡献表示 衷心感谢。 二、关于聘任副总经理的情况 截至本公告日，郭超先生、海洋先生未持有公司股份，不存在应履行而未履 行之承诺事项。 根据《中华人民共和国公司法》、《深圳证券交易所上市公司自律监管指引 第 1 号——主板上市公司规范运作》等相关法律、法规及《公司章程》的规定， 郭超先生、海洋先生的辞职报告自送达公司董事会之日起生效。 公司治理体系规范，组织梯队配置健全，相关工作有序承接，郭超先生、海 洋先生的辞职不会对 ...

证券代码：002737 证券简称：葵花药业 公告编号：2025-082 葵花药业集团股份有限公司 第五届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）第五届董事 会第十五次会议于 2025 年 12 月 30 日上午 9 时以通讯表决方式召开。会议由公 司董事长关玉秀女士召集，会议通知及议案于 2025 年 12 月 25 日通过电子邮件 形式发出。 会议应参加表决董事 9 人，实际参加表决董事 9 人。本次会议召集、召开程 序符合《公司法》及相关法律、法规以及《公司章程》之规定。会议决议合法有 效。 表决结果：同意 9 票，反对 0 票，弃权 0 票，通过。 专门委员会审议情况:本事项提交董事会审议前，业经公司第五届董事会提 1 名委员会 2025 年第三次会议审议通过、公司第五届董事会薪酬与考核委员会 2025 年第五次会议审议通过。 二、董事会会议审议情况 1、审议通过《关于聘任副总经理的议案》 同意聘任赵鹏先生担任公司副总经理职务，任期自董事会 ...

Core Viewpoint - The company announced that its wholly-owned subsidiary, Luling Kewhua, has acquired the marketing authorization and related production technology for Mesalazine enteric-coated tablets (0.5g specification) from Lifan Pharmaceutical for 34 million yuan (including tax) [1] Group 1: Transaction Details - The acquisition involves a change of the marketing authorization holder, which requires approval from the National Medical Products Administration [1] - The transaction does not constitute a related party transaction or a major asset restructuring [1] - The payment for the contract is divided into three installments, and the contract is valid until the marketing authorization holder is changed to Luling Kewhua and the production site is changed or increased to a designated site, completing verification of three batches of production and passing inspection [1] Group 2: Strategic Implications - The transaction aims to implement the "One Elderly" strategy, enrich the product pipeline, and strengthen the company's advantage in gastrointestinal medications [1]

Core Viewpoint - The pharmaceutical industry is crucial for public health and is a key focus of national policy, with companies like Kew Flower Pharmaceutical leading innovation and high-quality development in traditional Chinese medicine and modern pharmaceuticals [2][10]. Group 1: Company Overview - Kew Flower Pharmaceutical is a large brand pharmaceutical group primarily focused on traditional Chinese medicine, with a dual focus on chemical drugs, biological drugs, and health products [2][10]. - The company has shifted from a marketing-driven approach to a dual-driven strategy that emphasizes both marketing and product innovation, ensuring steady and high-quality development [2][10]. Group 2: Product Innovation - Kew Flower Pharmaceutical has introduced innovative products such as polyethylene glycol (PEG) for treating chronic constipation, which is based on a unique physical mechanism that does not involve metabolic participation or stimulation of intestinal nerves [4][5][7]. - The application of PEG in the treatment of constipation is still in the early stages in China, and Kew Flower Pharmaceutical is the first to introduce this technology domestically, aiming to improve the quality of life for patients [7][8]. Group 3: Industry Trends - The pharmaceutical industry is undergoing a transformation driven by policy support and technological breakthroughs, with a focus on high-quality value competition rather than low-level price competition [10][9]. - Kew Flower Pharmaceutical is committed to integrating traditional Chinese medicine with modern medical practices, focusing on the elderly, children, and women's health, which are key growth areas in the market [13]. Group 4: Digital Transformation - The company is actively investing in digitalization and smart technology to enhance operational efficiency and accelerate the innovation cycle in drug development, viewing digital transformation as a key driver for innovation [11][12]. - Kew Flower Pharmaceutical has developed a new digital work hub that integrates business processes, data interaction, and collaborative workflows, enhancing overall management capabilities [11]. Group 5: Future Outlook - The company plans to focus on core products and potential leading products, ensuring they meet quality standards and regulatory requirements to provide consumers with more choices [12]. - Kew Flower Pharmaceutical aims to leverage brand recognition and product quality to gain a competitive edge in the evolving pharmaceutical landscape [12].